<DOC>
	<DOCNO>NCT01704053</DOCNO>
	<brief_summary>The purpose study determine whether point care coagulation test able map anticoagulatory effect new oral anticoagulant dabigatran rivaroxaban . Used device thrombelastometry/-graphy ( ROTEM , TEG ) multiple platelet function analyzer ( Multiplate ) .</brief_summary>
	<brief_title>Effect New Oral Anticoagulants Dabigatran Rivaroxaban Point Care Coagulation Testing - Ex-Vivo Study</brief_title>
	<detailed_description>Patients receive dabigatran rivaroxaban therapeutic dos recruit . Blood take twice correlation time drug intake ( 3 hour drug intake ) . The result thrombelastometry/-graphy multiple platelet function analyzer compare directly concentration determine plasma concentration assay .</detailed_description>
	<mesh_term>Dabigatran</mesh_term>
	<mesh_term>Rivaroxaban</mesh_term>
	<mesh_term>Anticoagulants</mesh_term>
	<criteria>Patients receive Dabigatran Rivaroxaban Adults &gt; 18 year Patients receive concomittantly inhibitor platelet function Renal insufficiency ( Creatinine &gt; 1,5 mg/dl ) , Urea &gt; 80 mg/dl ) Hemodialysis Hepatic Dysfunction ( AST &gt; 30 U/l , ALT &gt; 30 U/l )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>New Oral Anticoagulants</keyword>
	<keyword>Dabigatran</keyword>
	<keyword>Rivaroxaban</keyword>
	<keyword>Thrombelastometry/-graphy ( ROTEM , TEG )</keyword>
	<keyword>Multiple Platelet Function Analyzer ( Multiplate )</keyword>
</DOC>